Interv Akut Kardiol. 2018;17(4):202-205 | DOI: 10.36290/kar.2018.027

Percutaneous pulmonary valve implantation

Ondřej Materna¹, Petr Tax¹, Petra Antonová², Jana Rubáčková Popelová³, Jan Janoušek¹, Oleg Reich¹

¹ Dětské kardiocentrum 2. LF UK a FN Motol, Praha

² Klinika kardiovaskulární chirurgie 2. LF UK a FN Motol, Praha

³ Centrum pro dospělé s vrozenou srdeční vadou, Nemocnice Na Homolce, Praha

Between 12/2011 and 7/2018, percutaneous pulmonary valve implantation (PPVI) was performed in 23 patients (8 women, 15 men).In 22 patients, the Melody TPV (Medtronic) valve was used. The Sapien valve (Edwards Lifescience) was implanted in one patient.The median age at implantation was 19.0 years (IQR 15.4–27.1). The median follow-up duration was 2.6 years (IQR 1.1–4.5, maximum5.9 years). There was no death during the whole follow-up period. PPVI resulted in an immediate improvement in the right ventricleto aortic pressure ratio and in a decrease in the right ventricle to pulmonary artery pressure gradient, p < 0.001. Echocardiographicmeasurements showed a decrease in the systolic pressure gradient over the right ventricular outflow tract, p < 0.001. Similarly, thedegree of pulmonary regurgitation improved, p < 0.001. During the follow-up period none of the patients needed another revalvulationprocedure. PPVI is an effective strategy for right ventricular outflow tract revalvulation with excellent mid-term results.

Keywords: congenital heart defect, conduit stenosis, conduit regurgitation, percutaneous pulmonary valve implantation

Accepted: October 12, 2018; Published: December 1, 2018  Show citation